Amryt Pharma Competitors

Revance Therapeutics (NASDAQ:RVNC) and Amryt Pharma (NASDAQ:AMYT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

74.4% of Revance Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 4.8% of Revance Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Revance Therapeutics and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Revance Therapeutics and Amryt Pharma, as provided by MarketBeat.

Revance Therapeutics currently has a consensus price target of $36.40, suggesting a potential upside of 29.40%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Revance Therapeutics.

Valuation & Earnings

This table compares Revance Therapeutics and Amryt Pharma's revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Revance Therapeutics. Amryt Pharma is trading at a lower price-to-earnings ratio than Revance Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Revance Therapeutics on 7 of the 13 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

80.6% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Dicerna Pharmaceuticals and Amryt Pharma, as provided by MarketBeat.

Dicerna Pharmaceuticals currently has a consensus price target of $37.8333, suggesting a potential upside of 45.01%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Dicerna Pharmaceuticals.

Valuation & Earnings

This table compares Dicerna Pharmaceuticals and Amryt Pharma's revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Dicerna Pharmaceuticals. Amryt Pharma is trading at a lower price-to-earnings ratio than Dicerna Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Dicerna Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Axsome Therapeutics (NASDAQ:AXSM) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends and profitability.

Insider & Institutional Ownership

63.6% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 26.0% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Axsome Therapeutics and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for Axsome Therapeutics and Amryt Pharma, as provided by MarketBeat.

Axsome Therapeutics currently has a consensus price target of $146.90, suggesting a potential upside of 177.22%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Amryt Pharma.

Valuation & Earnings

This table compares Axsome Therapeutics and Amryt Pharma's revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Axsome Therapeutics on 6 of the 11 factors compared between the two stocks.

NGM Biopharmaceuticals (NASDAQ:NGM) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares NGM Biopharmaceuticals and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for NGM Biopharmaceuticals and Amryt Pharma, as provided by MarketBeat.com.

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, suggesting a potential upside of 53.80%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than NGM Biopharmaceuticals.

Earnings and Valuation

This table compares NGM Biopharmaceuticals and Amryt Pharma's top-line revenue, earnings per share and valuation.

Amryt Pharma has lower revenue, but higher earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

NGM Biopharmaceuticals beats Amryt Pharma on 8 of the 14 factors compared between the two stocks.

Morphic (NASDAQ:MORF) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

61.5% of Morphic shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Morphic and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Morphic and Amryt Pharma, as provided by MarketBeat.com.

Morphic currently has a consensus price target of $63.3333, suggesting a potential upside of 6.71%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Morphic.

Earnings and Valuation

This table compares Morphic and Amryt Pharma's top-line revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Morphic on 8 of the 12 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and Amryt Pharma (NASDAQ:AMYT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

94.7% of Kura Oncology shares are owned by institutional investors. Comparatively, 15.4% of Amryt Pharma shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Kura Oncology and Amryt Pharma's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Kura Oncology and Amryt Pharma, as provided by MarketBeat.com.

Kura Oncology currently has a consensus price target of $39.5455, suggesting a potential upside of 38.42%. Amryt Pharma has a consensus price target of $38.00, suggesting a potential upside of 171.43%. Given Amryt Pharma's higher possible upside, analysts plainly believe Amryt Pharma is more favorable than Kura Oncology.

Earnings and Valuation

This table compares Kura Oncology and Amryt Pharma's top-line revenue, earnings per share and valuation.

Amryt Pharma has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Amryt Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

Amryt Pharma beats Kura Oncology on 7 of the 11 factors compared between the two stocks.